Fibrotic diseases, marked by excessive tissuescarring, represent another area where LIFR inhibitors could havea profound impact. Indeed, identifyingpotential therapeutic targets for liver fibrosis is important sinceliver fibrosis can advance to serious liver diseases like cirrhosisand hepatocellular carcinoma. InhibitingLIFR could help to mitigate fibrosis and enhance tissue function.The LIFR inhibitors have demonstrated potential in various therapeuticareas, although much of the research remains in the preclinical orearly clinical stages. This evidence concerns the gene LIFR and Hepatic fibrosis.